- Home
- MDGL vs FLR Comparison
MDGL vs FLR Comparison
Compare MDGL & FLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | FLR |
|---|---|---|
| Founded | 2011 | 1912 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 6.7B |
| IPO Year | 2005 | 2006 |
Fundamental Metrics
Financial Performance| Metric | MDGL | FLR |
|---|---|---|
| Price | $522.23 | $48.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $674.45 | $53.50 |
| AVG Volume (30 Days) | 358.6K | ★ 2.1M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $180,133,000.00 | ★ $15,503,000,000.00 |
| Revenue This Year | $58.39 | $6.15 |
| Revenue Next Year | $48.55 | $7.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $265.00 | $32.45 |
| 52 Week High | $615.00 | $57.50 |
Technical Indicators
Market Signals| Indicator | MDGL | FLR |
|---|---|---|
| Relative Strength Index (RSI) | 60.26 | 54.00 |
| Support Level | $503.93 | $42.92 |
| Resistance Level | $610.00 | $48.90 |
| Average True Range (ATR) | 19.77 | 1.47 |
| MACD | -0.09 | 0.22 |
| Stochastic Oscillator | 50.53 | 67.93 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About FLR Fluor Corporation
Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services.It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $15.5 billion in revenue in 2025.